
PBMs under fire for high drug prices, undermining independent pharmacies, harming patients – a slideshow
House Oversight Committee takes aim at pharmacy benefit managers.
The three top pharmacy benefit managers (PBMs) are “raising prescription drug prices, undermining community pharmacies, and harming patients across the United States,” according to the U.S. House Committee on Oversight and Accountability.
On July 23, Committee Chair Rep. James Comer (R-Kentucky) published “The Role of Pharmacy Benefit Managers in Prescription Drug Markets,” a report ahead of a
PBMs argue their large size would aid in increasing patient access while decreasing prescription drug costs. “Instead, the opposite has occurred: patients are seeing significantly higher costs with fewer choices and worse care,” the report said.
This slideshow contains key findings from the report and a statement by Comer, as published in an accompanying
Newsletter
Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.